The progress of novel androgen receptor inhibitors for non-metastatic castration-resistant prostate cancer / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 6-9, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-911164
ABSTRACT
Prostate cancer is one of the most common cancers threatening the health of males. The incidence of prostate cancer in China is on the rise. Non-metastatic castration-resistant stage is a special disease stage during the progression of prostate cancer, early identification of nmCRPC and prompt intervention can help delay disease progression and prolong patient survival. In recent years, many studies demonstrated the efficacy of novel androgen receptor inhibitors such as apalutamide, in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This article reviews the recent progress of novel androgen receptor inhibitors for nmCRPC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Urology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS